Form 8-K - Current report:
SEC Accession No. 0001213900-25-006727
Filing Date
2025-01-27
Accepted
2025-01-27 07:30:28
Documents
13
Period of Report
2025-01-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228747-8k_relmada.htm   iXBRL 8-K 30477
  Complete submission text file 0001213900-25-006727.txt   204822

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE rlmd-20250121.xsd EX-101.SCH 3012
3 XBRL LABEL FILE rlmd-20250121_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE rlmd-20250121_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0228747-8k_relmada_htm.xml XML 3705
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 25555779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)